The re-negotiation of its collaboration with Pharmaxis in December (a £5m upfront payment and 17% carried-interest in the LOXL-2 inhibitor programme) fully funds the Phase IIa trial for SNG001 (inhaled interferon-beta) in COPD, which has now started. With the near-term funding risk for the COPD programme eliminated, we introduce 2018 forecasts and a new target price of 35p based on a sum-of-the parts DCF. Should the pilot safety assessment for SNG001 in COPD and the Phase I trial for LO
07 Feb 2018
First patient dosed in COPD Phase IIa study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First patient dosed in COPD Phase IIa study
Synairgen plc (SNG:LON) | 5.1 0 0.0% | Mkt Cap: 10.3m
- Published:
07 Feb 2018 -
Author:
Mark Brewer | Cavendish Research -
Pages:
16
The re-negotiation of its collaboration with Pharmaxis in December (a £5m upfront payment and 17% carried-interest in the LOXL-2 inhibitor programme) fully funds the Phase IIa trial for SNG001 (inhaled interferon-beta) in COPD, which has now started. With the near-term funding risk for the COPD programme eliminated, we introduce 2018 forecasts and a new target price of 35p based on a sum-of-the parts DCF. Should the pilot safety assessment for SNG001 in COPD and the Phase I trial for LO